Abstract
Inflammasomes such as NOD-like receptor protein 1 (NLRP1), NLRP3,
NLR family CARD domain-containing protein 4 (NLRC4) and absent in melanoma 2
(AIM2) are the primary mediators of inflammation and its associated neuropathic pain.
These inflammasomes are activated leading to various autoimmune & metabolic
disorders, cancer, and other inflammatory diseases. The activation of inflammasomes
occurs due to molecular alterations like mitochondrial dysfunction, neuroinflammation,
lysosomal damage, oxidative stress, sensitization, and disinhibition, which lead to
proinflammatory pathways causing inflammasome-related neuropathic pain. Among
these inflammasomes, NLRP3 has been widely studied and proven to be the key player
in the development of neuropathy. In this chapter, we have summarized the role of
inflammasome and how NLRP3 is involved in neuropathic pain. Therefore, based on
the facts available, it has been suggested that focusing on inflammasome activity may
be a cutting-edge and successful treatment approach for neuropathic pain.